Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.